Tech Company Financing Transactions
BioLineRx Funding Round
Kreos Capital invested in a $40 million venture round for BioLineRx. The round was announced by the company on 9/15/2022.
Transaction Overview
Company Name
Announced On
9/15/2022
Transaction Type
Debt
Amount
$40,000,000
Round
Undisclosed
Investors
Kreos Capital (Chris Church)
Proceeds Purpose
BioLineRx intends to use the available funds from this agreement, together with cash on-hand, to support an aggressive commercial launch for Motixafortide in autologous stem cell mobilization for multiple myeloma patients, if approved, while it continues to evaluate U.S. commercialization strategies.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
2 HaMa'ayan St.
Modi'in, 7177871
Israel
Modi'in, 7177871
Israel
Phone
Website
Email Address
Overview
BioLineRx - A Drug Development Company
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Philip Serlin
Chief Financial Officer
Mali Zeevi
Chief Medical Officer
Abi Vainstein-Haras
VP - Bus. Development
Ella Sorani
Browse more venture capital transactions:
Prev: 9/15/2022: Excision Medical venture capital transaction
Next: 9/15/2022: Reku venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to record every notable VC transaction. VC transactions reported here are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs